Trading of ObsEva’s shares on SIX Swiss Exchange starts under the ticker symbol ‘OBSN’ Reference price at CHF 15.00 per share ObsEva with unique…
Category: Press release
The press releases from ObsEva
ObsEva SA Shares to Begin Trading on SIX Swiss Exchange
Listing of 45’381’252 registered shares with a par value of 1/13 of CHF 1 per share Anticipated market capitalisation of more…
ObsEva Announces Pricing of Follow-on Public Offering
Geneva, Switzerland and Boston, MA – June 20, 2018– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva Announces Launch of Proposed Follow-on Public Offering
Geneva, Switzerland and Boston, MA – June 18, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and…
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis
Partial suppression of estradiol with moderate dose (75mg) of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being…
ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018
Geneva, Switzerland and Boston, MA – June 15, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva SA to Seek SIX Share Listing
Geneva, Switzerland and Boston, MA -June 1, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization…
ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018
Geneva, Switzerland and Boston, MA -May 31, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results…
ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
Geneva, Switzerland and Boston, MA – May 8, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…